Grattan et al used the change urticaria activity score (UAS) to describe the response of a patient with chronic urticaria to therapy. The authors are from West Norwich Hospital, St. John's Institute of Dermatology and King's College in England.
Parameters:
(1) baseline urticaria activity score (UAS)
(2) urticaria activity score after an adequate trial of therapy
ratio of current to baseline UAS =
= (current UAS) / (baseline UAS)
Response criteria of Grattan et al
Ratio |
Response |
< 25% |
response |
> 75% |
relapse |
Response criteria expanded to include likely data
Ratio |
Response |
0% (current UAS 0) |
complete |
> 0 and < 25% |
positive response |
25 to 75% |
partial response |
> 75% (after initial response) |
relapse |
> 75% (with no initial response) |
persistent or stable |
> 120% |
progression |
where:
• The baseline UAS can range from 0 to 42 for a weekly UAS. The baseline needs to be above a certain level (? 14) to show a significant change.
• The patient should be assessed after an adequate therapeutic trial.
Purpose: To evaluate the response to therapy by a patient with chronic urticaria based on the study of Grattan et al.
Specialty: Immunology/Rheumatology, Dermatology
Objective: response to therapy
ICD-10: L50.9,